The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies
Abstract
A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cytokines can also antagonize each other's effects.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [58]
In the citing paper
“As cytokine signaling often shows redundancy (53–55), synergy (47), antagonistic effects (56–59) or signaling cascades (60), it seems advisable to take all cytokines that work together or against each other into account and thus measure a whole range instead of a single cytokine.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [58]
Citations
Cites
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129 · cited 1×
“There is no international consensus on how to divide asthma into these specific phenotypes, but recent work has focussed on ‘cluster analysis’, a method that groups people together with similar symptoms, signs and inflammatory features (Figure 2).(12,13) This method is useful to guide treatment according to how propor…”
MethodBritish Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987 · cited 2×
“Clinical phenotypes of asthma identified by cluster analysis, adapted from Haldar et al.(12) Clusters are plotted and divided into three categories (red) based on how proportional symptoms are to airway inflammation.”
MethodMepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755 · cited 1×
“A small proportion of patients with severe allergic asthma have persistently raised eosinophils levels in the sputum and blood, despite adequate treatment with corticosteroids after accounting for patient adherence to treatment.(43,44) IL-5, a cytokine that promotes eosinophil production and trafficking into the lungs…”
BackgroundLebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514 · cited 1×
“As per the anti-IL-5 antibody mepolizumab, this agent only demonstrated clinical effectiveness when the population was stratified for their eosinophilic pattern of airway inflammation.(55) Pitrakinra reduced allergen-induced late asthmatic responses and the need for rescue medication with minimal side effects.”
BackgroundMepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356 · cited 1×
“Mepolizumab, a monoclonal antibody against IL-5, significantly reduced exacerbation rates and improved quality of life in patients with severe refractory eosinophilic asthma.(46,47) This was associated with a reduction in sputum and blood eosinophils but did not improve symptoms, forced expiratory volume in 1 second (…”
BackgroundRothenberg, M. E., & Hogan, S. P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090720 · Cited by 1,356
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
WENZEL, S. E., SCHWARTZ, L. B., LANGMACK, E. L., HALLIDAY, J. L., TRUDEAU, J. B., GIBBS, R. L., & CHU, H. W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9812110 · Cited by 1,235 · cited 1×
“A small proportion of patients with severe allergic asthma have persistently raised eosinophils levels in the sputum and blood, despite adequate treatment with corticosteroids after accounting for patient adherence to treatment.(43,44) IL-5, a cytokine that promotes eosinophil production and trafficking into the lungs…”
Background
Research works printed but not linked: 11
- Carter PM, 1997, J Investig Allergol Clin Immunol, 7, 566
- Domingo RC, 1999, Rev Clin Esp, 199, 142
- Agbetile J, 2013, J Allergy Clin Immunol, 10
- Richeldi L, 2005, Cochrane Database Syst Rev, CD002997
- Wilkinson M, 2014, Cochrane Database Syst Rev, 5, CD001289
- Gauvreau GM, 2011, Respir Res, 140, 12
- 10.1016/S0140-6736(02)11679-5 · DOI · Paper page
- Castro M, 2014, Am J Respir Crit Care Med, 101, A3699
- Singh D, 2010, BMC Pulm Med, 3, 10
- Novelli F, 2013, Monaldi Arch Chest Dis, 79, 109
- Befekadu E, 2014, J Asthma Allergy, 7, 11
Cited by
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Skloot, G. S., Busse, P. J., Braman, S. S., Kovacs, E. J., Dixon, A. E., Fragoso, C. A. V., Scichilone, N., Prakash, Y. S., Pabelick, C. M., Mathur, S. K., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201608-658st · Cited by 125
Severe asthma: anti-IgE or anti-IL-5?
Papathanassiou, E., Loukides, S., & Bakakos, P. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.31813 · Cited by 36
Asthma Phenotypes and Endotypes: Implications for Personalised Therapy
Dean, K., & Niven, R. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0242-5 · Cited by 24
Self-citationLi, X., Liu, T., Mo, X., Wang, R., Kong, X., Shao, R., McIntyre, R. S., So, K., & Lin, K. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.389360 · Cited by 21
“For example, IL-4 amplifies IL-3 to induce differentiation and activation of mast cells in a synergistic way, but also blocks the secretion of IL-12 (Del Prete, 1992; Georas et al., 2005; Kane et al., 2015).”
Background
Metadata
- Authors
- Kane, B., Fowler, S. J., & Niven, R.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- Manchester Academic Health Science Centre, University Hospital of South Manchester, University of Manchester, Southmoor Road, Manchester, UK
- Corresponding author
- Kane, Binita
- ORCID
- Fowler, Stephen J
- Venue
- Chronic Respiratory Disease
- Publisher
- SAGE Publications
- Published
- 2014-12-09
- Volume
- 12
- Issue
- 1
- Pages
- 69-77
- ISSN
- 1479-9723 (ISSN-L)
- 1479-9731
- OpenAlex
- W2081294470
- Cited by
- 15
- References
- 65
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 2
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Chronic Respiratory Disease (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Occupational exposure and asthma
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- refractory asthma, severe asthma, adjuvant therapy, monoclonal antibodies, eosinophilic asthma, bronchial thermoplasty, asthma phenotypes, personalized asthma management
- MeSH terms
- Omalizumab, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antifungal Agents, Asthma, Bronchi, Bronchodilator Agents, Bronchoscopy, Fungi, Humans, Hypersensitivity, Hyperthermia, Induced, Tumor Necrosis Factor-alpha, Interleukin-4, Treatment Failure, Itraconazole, Anti-Asthmatic Agents, Macrolides, Phosphodiesterase 4 Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies. https://app.cochat.ai/papers/10.1177/1479972314562210
- The paper
- Kane, B., Fowler, S. J., & Niven, R. (2015). Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies. Chronic Respiratory Disease. https://doi.org/10.1177/1479972314562210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.